IL-32-dependent effects of IL-1β on endothelial cell functions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 10, 2009, Pages 3883-3888

  Nold Petry, Claudia A ^a   Nold, Marcel F ^a   Zepp, Jarod A ^a   Kim, Soo Hyun ^a   Voelkel, Norbert F ^b   Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Coagulation; Inflammation

Indexed keywords

CD141 ANTIGEN; CYTOKINE; DIFFERENTIATION ANTIGEN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; THROMBIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; INFLAMMATION; LUMINESCENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; THROMBOCYTE; WESTERN BLOTTING;

BLOOD PLATELETS; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; I-KAPPA B KINASE; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; INTERLEUKINS; LIPOPOLYSACCHARIDES; NF-KAPPA B; PROTEIN ISOFORMS; RNA, MESSENGER; RNA, SMALL INTERFERING; THROMBIN; THROMBOMODULIN; UMBILICAL VEINS;

EID: 62649165849     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0813334106     Document Type: Article

References (51)

1. Kim SH, et al. (2005) Interleukin-32: A cytokine and inducer of TNFalpha. Immunity 22:131-142.
2. Nold MF, et al. (2008) Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 181:557-565.
3. Goda C, et al. (2006) Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 18:233-240.
4. Netea MG, et al. (2006) Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 3:e277.
5. Shoda H, et al. (2006) Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 8:R166.
6. Rasool ST, et al. (2008) Increased level of IL-32 during human immunodeficiency virus infection suppresses HIV replication. Immunol Lett 117:161-167.
7. Li W, et al. (2008) Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS ONE 3:e1985.
8. Calabrese F, et al. (2008) IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178:894-901.
9. Netea MG, et al. (2005) IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 102:16309-16314.
10. Shioya M, et al. (2007) Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 149:480-486.
11. Dinarello CA, Kim SH (2006) IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65(Suppl 3):iii61-iii64.
12. Cagnard N, et al. (2005) Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 16:289-292.
13. Edwards CJ, et al. (2007) Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med 13:40-58.
14. Joosten LA, et al. (2006) IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 103:3298-3303.
15. Marcondes AM, et al. (2008) Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 105:2865-2870.
16. Rossi V, et al. (1985) Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 229:174-176.
17. Dinarello CA (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201:1355-1359.
18. Introna M, et al. (1994) Pro- and anti-inflammatory cytokines: Interactions with vascular endothelium. Clin Exp Rheumatol 10(Suppl):S19-23.
19. Voelkel NF, Tuder R (1994) Interleukin-1 receptor antagonist inhibits pulmonary hypertension induced by inflammation. Ann N Y Acad Sci 725:104-109.
20. Goldbach-Mansky R, et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355:581-592.
21. Loppnow H, et al. (1998) Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 91:134-141.
22. Mandinov L, et al. (2003) Interleukin 1: The choreographer for the restenotic ballet. Thromb Haemost 90:369-371.
23. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275-285.
24. Voelkel NF, Tuder RM (1995) Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 8:2129-2138.
25. Voelkel NF, Cool CD (2003) Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J 46(Suppl):28s-32s.
26. Cook-Mills JM, Deem TL (2005) Active participation of endothelial cells in inflammation. J Leukoc Biol 77:487-495.
27. Dinarello CA (2002) The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 20(5 Suppl 27):S1-13.
28. Dustin ML, et al. (1986) Induction by IL 1 and interferon-gamma: Tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137:245-254.
29. Galkina E, Ley K (2007) Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 27:2292-2301.
30. Steffens S, Mach F (2004) Inflammation and atherosclerosis. Herz 29:741-748.
31. Lebedeva T, Dustin ML, Sykulev Y (2005) ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 17:251-258.
32. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095-2147.
33. Griffioen AW (2008) Anti-angiogenesis: Making the tumor vulnerable to the immune system. Cancer Immunol Immunother 57:1553-1558.
34. Esmon CT, Esmon NL, Harris KW (1982) Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 257:7944-7947.
35. Esmon CT (2006) Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 32(Suppl 1):49-60.
36. Nold MF, et al. (2007) Activated protein C downregulates p38 mitogen-activated protein kinase and improves clinical parameters in an in-vivo model of septic shock. Thromb Haemost 98:1118-1126.
37. Joyce DE, et al. (2001) Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276:11199-11203.
38. Van de Wouwer M, Conway EM (2004) Novel functions of thrombomodulin in inflammation. Crit Care Med 32(5 Suppl):S254-S261.
39. Vande Wouwer M, et al. (2006) The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 4:1813-1824.
40. Conway EM, et al. (2002) The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 196:565-577.
41. Li YH, et al. (2001) Functional mutation in the promoter region of thrombomodulin gene in relation to carotid atherosclerosis. Atherosclerosis 154:713-719.
42. Li YH, et al. (2002) Synergistic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Haemost 87:86-91.
43. Waugh JM, et al. (2000) Thrombomodulin overexpression to limit neointima formation. Circulation 102:332-337.
44. Weiler H, Isermann BH (2003) Thrombomodulin. J Thromb Haemost 1:1515-1524.
45. Roubenoff R, et al. (2003) Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: The Framingham Heart Study. Am J Med 115:429-435.
46. Braunersreuther V, Mach F, Steffens S (2007) The specific role of chemokines in atherosclerosis. Thromb Haemost 97:714-721.
47. Kamari Y, et al. (2007) Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 195:31-38.
48. Maier JA, Voulalas P, Roeder D, Maciag T (1990) Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science 249:1570-1574.
49. McMahon GA, et al. (1997) Intracellular precursor interleukin (IL)-1alpha, but not mature IL-1alpha, is able to regulate human endothelial cell migration in vitro. J Biol Chem 272:28202-28205.
50. Tashiro H, et al. (2001) Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis 12:107-113.
51. Lindeman JH, et al. (2008) Enhanced expression and activation of pro-inflammatory transcription factors distinguish aneurysmal from atherosclerotic aorta: IL-6- and IL-8-dominated inflammatory responses prevail in the human aneurysm. Clin Sci (Lond) 114:687-697.